PhenomeX Inc. & Bruker Corporation Enter Official Contract for Bruker to Obtain PhonemeX in a Cash Purchase

PhenomeX’s equity worth as of the planned purchase is roughly $108 million.

In order to promote and advance the well-being of humans, PhenomeX, a business that specialises in functional cell biology, equips researchers to take advantage of every cell’s potential.

“This is an important next step for PhenomeX as we bring together two companies passionate about innovating for our customers to support human health”

Earlier this year, PhenomeX was established, and has over than 400 products in its portfolio.

With tools, online platforms and cellular biology components, PhenomeX offers single-cell biological workflows.

One example is the Beacon Optofluidic system, which helps scientists to speed up the development of biological goods by integrating phenotypes, genetics and multiomic data.

CEO of Bruker NANO Group, Professor Mark R. Munch stated, “The unique single-cell analysis platforms of PhenomeX are enabling researchers to more rapidly and precisely unlock new insights in functional cell biology research leading to important discoveries across the large and rapidly growing markets of antibody therapeutics, cell line development, cell therapy and gene therapy.

“This is an important next step for PhenomeX as we bring together two companies passionate about innovating for our customers to support human health,” commented Siddhartha Kadia, CEO at PhenomeX

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved